Onychomycosis Market Report 2026

Onychomycosis Market Overview

• Onychomycosis market size has reached to $3.81 billion in 2025 • Expected to grow to $5.09 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Diabetic Population Fuels Onychomycosis Market Growth • Market Trend: Innovative Formulations Transform Onychomycosis Treatment Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Onychomycosis Market?

Onychomycosis is a fungal infection that affects the nail matrix, bed, or plate, and can impact both toenails and fingernails, leading to discoloration, thickening, and nail crumbling. The goal of treatment is to eradicate the infection, restore the nail's health and appearance, and prevent the fungus from spreading to other nails or skin. The main types of onychomycoses are distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, and others. Distal subungual onychomycosis (DSO) is a fungal infection affecting the feet’ nails, which can be treated in several ways, such as with oral antifungal drugs, topical antifungal treatments, or sometimes both. The treatment includes drug treatment, topical therapy, and others, which are distributed by hospitals pharmacies, retail pharmacies, and others.

What Is The Onychomycosis Market Growth Forecast?

The onychomycosis market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising demand for combination therapies, increasing adoption of teledermatology and remote monitoring, growing development of ai-assisted diagnostic solutions, expansion of hospital and retail pharmacy distribution, increasing investment in research for resistant fungal strains. Major trends in the forecast period include rising adoption of personalized antifungal therapies, increasing use of teledermatology for diagnosis and monitoring, growing implementation of ai-based diagnostic tools for nail infections, rising awareness about nail health and hygiene, increasing development of combination drug and topical therapies.

Global Onychomycosis Market Segmentation

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types 2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections 2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections 3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients 4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections 5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis

What Is The Driver Of The Onychomycosis Market?

The surge in the diabetic patient population is expected to propel the growth of the onychomycosis market going forward. Diabetes is a chronic disease caused by either insufficient insulin synthesis by the pancreas or ineffective insulin utilization by the body. Onychomycosis is a common foot problem for people with diabetes, which can be managed by preventing and managing complications associated with onychomycosis. Hence, the rising incidence of diabetes boosts the demand for the onychomycosis market. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the rising incidence of diabetes is driving the growth of the onychomycosis industry.

Key Players In The Global Onychomycosis Market

Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy's Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

Global Onychomycosis Market Trends and Insights

Major companies operating in the onychomycosis market are developing innovative formulations for products to sustain their position in the market. Innovative formulations contribute to the advancement of the onychomycosis market by improving treatment outcomes and addressing specific challenges associated with the condition. For instance, in February 2024, Moberg Pharma AB, a Sweden-based pharmaceutical company, launched MOB-015. It is a proprietary topical formulation of terbinafine designed to deliver effective concentrations directly to the nail and nail bed, minimizing the risk of systemic exposure associated with oral terbinafine. It has received recommendations for national approval in 13 European countries and is marketed in Sweden under the brand name Terclara. The approval is backed by two Phase 3 trials, which showed that MOB-015 achieved superior mycological cure rates (76% compared to up to 42% for comparators) and a significantly higher complete cure rate with no serious adverse reactions reported.

What Are Latest Mergers And Acquisitions In The Onychomycosis Market?

In July 2023, Cipher Pharmaceuticals Inc., a Canada-based pharmaceutical company, partnered with Moberg Pharma to MOB-015 for nail fungus treatment. The partnership aims to commercialize MOB-015, a topical nail fungus treatment with superior clinical cure rates, and Moberg Pharma secured EU approval and plans to launch the product across 13 European countries. Moberg Pharma AB is a Sweden-based pharmaceutical company that provides treatment for onychomycosis.

Regional Outlook

North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Onychomycosis Market?

The onychomycosis market includes revenues earned by services such as combination therapy, oral antifungal medications, itraconazole, ketoconazole, griseofulvin, and terbinafine. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Onychomycosis Market Report 2026?

The onychomycosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the onychomycosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.